Exelixis announced that the company’s Board of Directors has authorized the repurchase of up to $550M the company’s common stock before the end of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
- Exelixis initiated with an Overweight at Wells Fargo
- Exelixis says Phase 3 CONTACT-03 study did not meet its primary endpoint
- Bristol-Myers’ Opdivo and Exelixis’ Cabometyx show durable survival in carcinoma
- Exelixis, Sairopa announce FDA clearance for ADU-1805 IND application
- Exelixis sees FY23 revene $1.775B-$1.875B, consensus $1.84B
Questions or Comments about the article? Write to editor@tipranks.com